Yahoo · Nov 17, 2026
Should You Continue to Hold ALGN Stock in Your Portfolio?
Align Technology's Invisalign expansion, strategic alliances and strong stock gains support its prospects, but currency volatility and competition pose risks.
NYSE · PAHC
Healthcare · Drug Manufacturers - Specialty & Generic
$34.08
Down-$1.49 (-4.19%)
Updated Nov 20, 2026, 10:55 AM
SID Score
4.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · PAHC
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 19, 2026
PAHC closed at $34.08 after 21 trading sessions, down 14.39% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 19, 2026 | $35.37 | $35.37 | $33.91 | $34.08 | 101.72K |
| Nov 18, 2026 | $34.56 | $35.74 | $34.50 | $35.57 | 109.17K |
| Nov 17, 2026 | $34.90 | $35.635 | $34.26 | $34.92 | 130.09K |
| Nov 16, 2026 | $36.04 | $36.075 | $34.835 | $35.02 | 193.57K |
| Nov 13, 2026 | $35.69 | $36.40 | $35.15 | $35.97 | 293.91K |
| Nov 12, 2026 | $35.19 | $35.51 | $34.79 | $35.46 | 130.13K |
| Nov 11, 2026 | $34.58 | $35.30 | $34.28 | $35.15 | 145.58K |
| Nov 10, 2026 | $34.48 | $35.24 | $33.98 | $34.64 | 223.79K |
| Nov 9, 2026 | $33.33 | $35.03 | $33.07 | $34.61 | 282.68K |
| Nov 6, 2026 | $35.21 | $35.67 | $32.91 | $32.96 | 283.68K |
| Nov 5, 2026 | $38.09 | $39.46 | $35.00 | $35.40 | 348.69K |
| Nov 4, 2026 | $38.61 | $39.715 | $38.315 | $39.43 | 266.66K |
| Nov 3, 2026 | $38.93 | $39.53 | $37.35 | $37.65 | 289.49K |
| Nov 2, 2026 | $39.41 | $40.54 | $38.05 | $38.74 | 250.44K |
| Oct 30, 2026 | $39.38 | $39.95 | $38.49 | $38.88 | 182.78K |
| Oct 29, 2026 | $38.35 | $39.01 | $38.275 | $38.86 | 100.83K |
| Oct 28, 2026 | $38.18 | $38.455 | $37.60 | $37.88 | 168.86K |
| Oct 27, 2026 | $38.95 | $39.26 | $38.30 | $38.38 | 118.87K |
| Oct 26, 2026 | $38.80 | $39.57 | $38.70 | $39.03 | 144.65K |
| Oct 23, 2026 | $39.51 | $39.51 | $38.62 | $38.80 | 102.86K |
| Oct 22, 2026 | $39.37 | $40.87 | $39.28 | $39.81 | 254.38K |
The latest Smart Investors Daily articles mentioning PAHC.
Company
Market Activity
Research & News
PAHC research
Company profile and research snapshot.
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 14, 2026 | Citigroup | Neutral | — |
| Apr 15, 2026 | Citigroup | Neutral | — |
| Nov 7, 2025 | JP Morgan | Overweight | — |
| Aug 29, 2025 | B of A Securities | Underperform | — |
| Jul 7, 2025 | JP Morgan | Overweight | — |
No generated briefing is available yet.
Yahoo · Nov 17, 2026
Align Technology's Invisalign expansion, strategic alliances and strong stock gains support its prospects, but currency volatility and competition pose risks.
Yahoo · Nov 13, 2026
Envista's global expansion, new product launches and improving margins support growth, but competitive pressures and currency headwinds pose challenges.
Yahoo · Nov 13, 2026
BRKR's diagnostics growth, preclinical imaging expansion and $140 million cost-savings target support its outlook, but uneven academic demand and macroeconomic uncertainty pose risks.
Yahoo · Nov 11, 2026
For questions about this article or underlying research, email [email protected].
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning PAHC.